Maintenance of an Antiaggregation by Acetylsalicylic Acid, While a Extracorporeal Lithotripsy Session on a Kidney Stone is Perfomed: Comparative Unicentric Prospective Study

Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Feb 12, 2018

Keywords

ClinConnect Summary

This clinical trial is investigating whether patients who are taking a low dose of aspirin (250 mg or less) can safely continue their medication during a specific treatment for kidney stones called extracorporeal lithotripsy (ECL). ECL is a procedure that uses shock waves to break up kidney stones into smaller pieces so they can be more easily passed. The study aims to see if continuing aspirin might lead to fewer complications, like bleeding or hematomas (bruises) around the kidneys, while still effectively treating the stones.

To participate in this trial, individuals must be over 18 years old and have at least one kidney stone that requires ECL treatment. They must also be taking a specific type of aspirin called Kardégic 75. Potential participants should not have any bleeding disorders, be on other blood-thinning medications, or have any other conditions that would prevent safe participation in the ECL procedure. If eligible, participants can expect to receive the ECL treatment while continuing their aspirin, and they will be monitored for any side effects or complications related to the procedure. This study is important as it could help simplify treatment for patients who need to manage both kidney stones and cardiovascular health.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Over 18 yo patients
• • Patients with 1 renal lithiasis (at least) requiring treatment with extracorporeal lithotripsy
• • Patients taking Kardégic 75 (monotherapy
• Exclusion Criteria:
• • Patients with known (or previously known) bleeding disorders on the pre-treatment assessment
• • Patients with anticoagulant therapy or other anti-aggregating therapy (eg Kardegic at 75mg, AVK, NACO, LMWH, HNF, P2Y12 inhibitor)
• • Patients with another contrindication to the ECL.
• • Patients with prescription of more than the outset 1 ECL session
• • Tutelage, curatorship, justice safeguarding, deprived of liberties, unaffiliated SS, impaired comprehension abilities, pregnant and lactating women.